Get the Stockscreener App
1.81
5.24%
-0.10
Pre-market:
1.80
-0.01
-0.55%
Gain Therapeutics Inc stock is traded at $1.81, with a volume of 564.98K.
It is down -5.24% in the last 24 hours and up +6.47% over the past month.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
See More
Previous Close:
$1.91
Open:
$1.91
24h Volume:
564.98K
Relative Volume:
0.72
Market Cap:
$77.20M
Revenue:
$55,200
Net Income/Loss:
$-21.24M
P/E Ratio:
-3.0756
EPS:
-0.5885
Net Cash Flow:
$-19.37M
1W Performance:
-8.59%
1M Performance:
+6.47%
6M Performance:
-29.02%
1Y Performance:
+7.10%
1-Day Range:
$1.80
$1.9358
1-Week Range:
$1.80
$2.24
52-Week Range:
$1.41
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.81 | 86.59M | 55,200 | -21.24M | -19.37M | -0.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
GANX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval - Investing.com
Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained - TipRanks
Price to sales forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Number of shareholders of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Gain Therapeutics Receives FDA Clearance to Initiate Phase 2 Trial of GT-02287 for Parkinson’s Disease - Minichart
Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines - Moomoo
Why Is GANX Stock Rallying 22% After Hours? - Asianet Newsable
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial - TipRanks
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug By Investing.com - Investing.com India
Gain Therapeutics Gets US FDA Approval to Advance GT-02287 Into Phase 2 Study for Parkinson's Disease - marketscreener.com
Gain Therapeutics receives FDA clearance for Parkinson’s drug trial - Investing.com
Gain Therapeutics (GANX) wins FDA IND clearance to start GT-02287 Phase 2 Parkinson’s trial - Stock Titan
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease - The Manila Times
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 Into Phase 2 Development for Parkinson's Disease - Moomoo
FDA clears Gain Therapeutics drug GT-02287 for Phase 2 Parkinson’s trial - Stock Titan
Price to earnings forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Gain Therapeutics Inc (GANX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gain Therapeutics, Inc. Announces 2026 Shareholder Vote Results and Emerging Growth Company Status (GANX) - Minichart
Gain Therapeutics, Inc. Actuals & Estimates (NASDAQ:GANX) - TradingView
Gain Therapeutics Shareholders Confirm Board and Auditor Choices - TipRanks
Gain Therapeutics (GANX) shareholders back board slate and Ernst & Young AG at 2026 meeting - Stock Titan
GANX Forecast — Price Target — Prediction for 2027 - TradingView
3 Clinical-Stage Biotech Stocks Worth Watching In Parkinson's Research - Sahm
Gain Therapeutics Inc (GANX) Institutional Confidence - TradingKey
Gain Therapeutics Inc (GANX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gain Therapeutics Inc (GANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GAIN THERAPEUTICS INC (GANX) Stock Chart - ChartMill
Gain Therapeutics Inc (GANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Gain Therapeutics Inc (GANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Gain Therapeutics Inc (GANX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gain Therapeutics Inc (GANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viking Therapeutics, Inc. (VKTX) gains as market dips: What you should know - MSN
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know - Yahoo Finance
Gain Therapeutics Inc. (GANX) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesRevenue Guidance Range - newsline.com
GANX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - The Manila Times
Biotech Gain Therapeutics joins H.C. Wainwright Neuro expert summit - Stock Titan
Bial Ends Development Of Parkinson’s Disease Drug After Phase IIb Fail - Citeline News & Insights
Niemann-Pick Type Pipeline Gains Momentum: 10+ Companies Lead - openPR.com
Which stocks are moving after the closing bell on Monday? - ChartMill
Dyne Therapeutics (DYN) investors double share authorization and approve all proposals - Stock Titan
TVTX: FILSPARI cements its role in rare kidney disease, with robust growth and pipeline innovation - TradingView
Tango Therapeutics Shares Surge 32% on Strong Clinical Momentum in Precision Oncology - International Business Times Australia
Monday's pre-market session: top gainers and losers - ChartMill
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
OPKO Health (OPK) Amends Partnership With Nicoya Therapeutics to Gain Equity Stake - Insider Monkey
Gain Therapeutics (GANX) price target increased by 11.76% to 7.75 - MSN
4 Biotech Stocks Investors Should Watch in 2026 - TradingView
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):